YUAN Sha-sha,WANG Ning,MIAO Qing.Clinical Observation of Bupi Qingfei Decoction in Treatment ofBronchiectasis Colonized by Pseudomonas aeruginosa[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(24):118-124.
YUAN Sha-sha,WANG Ning,MIAO Qing.Clinical Observation of Bupi Qingfei Decoction in Treatment ofBronchiectasis Colonized by Pseudomonas aeruginosa[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(24):118-124. DOI: 10.13422/j.cnki.syfjx.20212493.
Clinical Observation of Bupi Qingfei Decoction in Treatment ofBronchiectasis Colonized by Pseudomonas aeruginosa
To evaluate the clinical efficacy of Bupi Qingfei decoction in the treatment of bronchiectasis colonized by
Pseudomonas aeruginosa
(PA) (lung-spleen Qi deficiency syndrome and phlegm heat accumulating in lung syndrome).
Method
2
A total of 72 bronchiectasis patients colonized with PA ( lung-spleen Qi deficiency syndrome and phlegm heat accumulating in lung syndrome ) were randomly divided into the observation group (36 cases, two cases were lost to follow-up and three dropped out) and control group (36 cases, three cases were lost to follow-up and four dropped out). There were 31 cases in the observation group and 29 cases in the control group completing the trial. Patients in the observation group were treated with Bupi Qingfei decoction orally,once in the morning and again in the evening, one bag every other day, and simulated azithromycin tablet at the dose of 0.5 g,once every other day, while those in the control group with azithromycin tablet at 0.5 g,once every other day, and simulated Bupi Qingfei decoction, once in the morning and again in the evening, one bag every other day. Patients in both groups received health education and postural expectoration. The treatment lasted for 24 weeks,followed by a 24-week follow-up. The frequency of acute exacerbation,quality of life (St. George's Respiratory Questionnaire) score,traditional Chinese medicine (TCM) syndrome score,lung function [forced expiratory volume in one second percentage of predicted(FEV
1
%pred) and FEV
1
/forced vital capacity(FVC)], and serum immunoglobulin (Ig)A,IgE,IgG,and IgM levels of the two groups were evaluated after treatment.
Result
2
The frequencies of acute exacerbation after 24 weeks of treatment and during the 24-week follow-up in the observation group were lower than those in the control group (
P
<
0.05). The total quality of life (St. George's Respiratory Questionnaire) score and symptom scores in the observation group after 24 weeks of treatment were significantly decreased as compared with those before treatment (
P
<
0.05). There was no significant improvement in the quality of life in the control group either after 24 weeks of treatment or during the 24-week follow-up. The effective rate against TCM syndrome in the observation group was 64.52%(20/31) after 12 weeks of treatment,which was obviously higher than 31.03%(9/29) in the control group (
χ
2
=6.726,
P
<
0.05). After 24 weeks of treatment,the effective rate in the observation group was 83.87%, slightly higher than 68.97% in the control group. After 12 and 24 weeks of treatment,the scores of cough,expectoration,fatigue,anorexia,spontaneous sweating,abdominal distension, and loose stool in the observation group were better than those in the control group (
P
<
0.05). There were no significant changes in lung function and serum immunoglobulin classes in the two groups.
Conclusion
2
Bupi Qingfei decoction is effective in reducing the frequency of acute exacerbation, alleviating the symptoms, and improving the quality of life of bronchiectasis patients colonized by PA (lung-spleen Qi deficiency syndrome and phlegm heat accumulating in lung syndrome).
关键词
支气管扩张症铜绿假单胞菌补脾清肺汤阿奇霉素急性加重次数生活质量
Keywords
bronchiectasisPseudomonas aeruginosa(PA)Bupi Qingfei decoctionazithromycinfrequency of acute exacerbationquality of life
TUNNEY M M,EINARSSON G G,WEI L,et al.Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation[J].Am J Respir Crit Care Med,2013,187(10):1118 -1126.
CHALMERS J D,SMITH M P,MCHUGH B J,et al.Shortand longterm antibiotic treatment reduces airway and systemic inflammation in noncystic fibrosis bronchiectasis[J].Am J Respir Crit Care Med,2012,186(7):657-665.
DAVIES G,WELLS A U,DOFFMAN S,et al.The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis[J].Eur Respir J,2006,28(5):974-979.
CHAWLA K,VISHWANATH S,MANU M K,et al.Influence of pseudomonas aeruginosa on exacerbation in patients with bronchiectasis[J].J Glob Infect Dis,2015,7(1):18-22.
WILSON C B,JONES P W,O′LEARY C J,et al.Effect of sputum bacteriology on the quality of life of patients with bronchiectasis[J].Eur Respir J,1997,10(8):1754-1760.
LOEBINGER M R,WELLS A U,HANSELL D M,et al.Mortality in bronchiectasis:a longterm study assessing the factors influencing survival[J].Eur Respir J,2009,34(4):843-849.
WANG R C,DING S Z,LEI C,The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis:a prospective cohort study[J].Ann Med,2021,53(1):459-469.
CHALMERS J D,BOERSMA W,LONERGAN M,et al.Long-term macrolide antibiotics for the treatment of bronchiectasis in adults:an individual participant data meta-analysis[J].Lancet Respir Med,2019,7(10):845-854.
CONROY W,LATA J,NOELETAL K,et al.Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE):a randomised,double-blind,placebo-controlled trial[J].Lancet,2012,380(9842):660-667.
SERISIER D J ,MARTIN M L ,MCGUCKIN M A ,et al.Effect of long-term,low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis:the BLESS randomized controlled trial [J].JAMA,2013,309(12):1260-1267
HILL A T,HAWORTH C S,ALIBERTI S,et al.Pulmonary exacerbation in adults with bronchiectasis:a consensus definition for clinical research[J].Eur Respir J,2017,49(6):1700051.
JONES P W,QUIRK F H,BAVEYSTOCK C M.The St Georg's respiratory questionnaire[J].Respir Med,1991,85(Suppl B):25-31.
RYALL B,DAVIES J C,WILSON R,et al.Pseudomonas aeruginosa,cyanide accumulation and lung function in CF and nonCF bronchiectasis patients[J].Eur Respir J,2008,32(3):740-747.
LUO R G,MIAO X Y,LUO L L,et al.Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients[J].Clin Microbiol Infect,2019,25(5):601-606.
ALTENBURG J,DE GRAAFF C S,STIENSTRA Y,et al.Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis:the BAT randomized controlled trial[J].JAMA,2013,309(12):1251-1259.